232 related articles for article (PubMed ID: 20211672)
1. Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins.
Kersanté F; Moulédous L; Zajac JM; Mollereau C
Neurochem Int; 2010; 56(6-7):768-73. PubMed ID: 20211672
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
3. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
4. Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain.
Shaqura MA; Zöllner C; Mousa SA; Stein C; Schäfer M
J Pharmacol Exp Ther; 2004 Feb; 308(2):712-8. PubMed ID: 14593084
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells.
Mollereau C; Mazarguil H; Zajac JM; Roumy M
Mol Pharmacol; 2005 Mar; 67(3):965-75. PubMed ID: 15608144
[TBL] [Abstract][Full Text] [Related]
6. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
7. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
8. Mu-delta opioid receptor functional interaction: Insight using receptor-G protein fusions.
Snook LA; Milligan G; Kieffer BL; Massotte D
J Pharmacol Exp Ther; 2006 Aug; 318(2):683-90. PubMed ID: 16690720
[TBL] [Abstract][Full Text] [Related]
9. Biochemical anti-opioid action of NPFF2 receptors in rat spinal cord.
Gouardères C; Zajac JM
Neurosci Res; 2007 May; 58(1):91-4. PubMed ID: 17337079
[TBL] [Abstract][Full Text] [Related]
10. Staurosporine differentiation of NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells induces selectivity of NPFF activity towards opioid receptors.
Mollereau C; Zajac JM; Roumy M
Peptides; 2007 May; 28(5):1125-8. PubMed ID: 17418451
[TBL] [Abstract][Full Text] [Related]
11. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Clark MJ; Traynor JR
J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
[TBL] [Abstract][Full Text] [Related]
12. GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.
Moulédous L; Froment C; Dauvillier S; Burlet-Schiltz O; Zajac JM; Mollereau C
J Biol Chem; 2012 Apr; 287(16):12736-49. PubMed ID: 22375000
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide FF-sensitive confinement of mu opioid receptor does not involve lipid rafts in SH-SY5Y cells.
Moulédous L; Merker S; Neasta J; Roux B; Zajac JM; Mollereau C
Biochem Biophys Res Commun; 2008 Aug; 373(1):80-4. PubMed ID: 18544342
[TBL] [Abstract][Full Text] [Related]
14. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections.
Martin TJ; Sim LJ; Selley DE; deMontis MG; Childers SR
Synapse; 1997 Nov; 27(3):177-82. PubMed ID: 9329153
[TBL] [Abstract][Full Text] [Related]
15. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
16. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats.
Chen F; Lawrence AJ
J Pharmacol Exp Ther; 2004 Sep; 310(3):1020-6. PubMed ID: 15121763
[TBL] [Abstract][Full Text] [Related]
17. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.
Vogt LJ; Sim-Selley LJ; Childers SR; Wiley RG; Vogt BA
J Pharmacol Exp Ther; 2001 Dec; 299(3):840-8. PubMed ID: 11714867
[TBL] [Abstract][Full Text] [Related]
18. Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model.
Kersanté F; Mollereau C; Zajac JM; Roumy M
Peptides; 2006 May; 27(5):980-9. PubMed ID: 16488058
[TBL] [Abstract][Full Text] [Related]
19. Effect of chronic ethanol and withdrawal on the mu-opioid receptor- and 5-Hydroxytryptamine(1A) receptor-stimulated binding of [(35)S]Guanosine-5'-O-(3-thio)triphosphate in the fawn-hooded rat brain: A quantitative autoradiography study.
Chen F; Lawrence AJ
J Pharmacol Exp Ther; 2000 Apr; 293(1):159-65. PubMed ID: 10734165
[TBL] [Abstract][Full Text] [Related]
20. COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression.
Berthele A; Platzer S; Jochim B; Boecker H; Buettner A; Conrad B; Riemenschneider M; Toelle TR
Neuroimage; 2005 Oct; 28(1):185-93. PubMed ID: 16040257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
